plc (NASDAQ: ALKS) today announced the initiation of FORWARD-5, the
third of three core efficacy studies planned in the pivotal clinical
program for ALKS 5461, a once-daily, oral investigational medicine with
a novel mechanism of action for the adjunctive treatment of major
depressive disorder (MDD). The study will evaluate the efficacy and
safety of ALKS 5461 in patients suffering from MDD who have had an
inadequate response to commonly prescribed drugs for depression,
including selective serotonin reuptake inhibitors (SSRIs) or
serotonin-norepinephrine reuptake inhibitors (SNRIs). Approximately
two-thirds of patients who are diagnosed with MDD do not adequately
respond to initial antidepressant therapy.
plc (NASDAQ: ALKS) today announced the initiation of a phase 1
clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule
in development for the treatment of multiple sclerosis (MS). The
randomized, double-blind study will evaluate the safety, tolerability
and pharmacokinetics of several oral formulations of ALKS 8700 compared
to both placebo and active control groups in approximately 125 healthy
SoundCure, a medical device company whose mission is to revolutionize
the treatment of tinnitus, today announced the results of a randomized,
multi-center clinical study that found S-Tones® to be effective at quiet
volumes and to be more effective than broadband noise in the reduction
of tinnitus, a condition often called, “ringing in the ears.”
The study, conducted by leading tinnitus researchers at three top
audiology centers, and led by internationally renowned Dr.
Company's research partner, Trauma Research, LLC will present key clinical validation data from a prospective trial utilizing the RedoxSYS™ Diagnostic System and oxidation-reduction potential (ORP)
Sign-up for Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting investment picks
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol
(LDL-cholesterol) lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers, today
announced dosing of the first patient in its Phase 2 clinical study of
ETC-1002 in patients with hypercholesterolemia and hypertension,
Celgene Corporation (NASDAQ:CELG) today announced that results of a
study evaluating the combination of REVLIMID® (lenalidomide) with
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine
sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell
lymphoma (DLBCL) were published online ahead of print in the Journal
of Clinical Oncology .
Sign-up for Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate investment picks
PhotoMedex, Inc. (NasdaqGS and TASE:PHMD) today announced that a
new independent clinical study demonstrated a substantial reduction in
hair regrowth following use of no!no! Hair using proprietary
OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and
diagnostics company, yesterday hosted a webcast presenting outstanding
interim six-month results from a Phase 2 study of its long-acting human
growth hormone product Lagova to treat pediatric growth hormone
deficiency disorder (GHD).
During the webcast, Dr.
Long-Acting VRS-317 Efficacy and Safety Comparable to Daily Growth Hormone Therapies
CHICAGO, June 23, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR) , an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today presented positive Phase 2a data from its six month clinical trial demonstrating the safety and efficacy of VRS-317 in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD). These results are being presented by George Bright, MD, Versartis Vice President of Clinical Development, during the clinical poster session, "Growth and GH: Diagnostic Issues and Treatment" from 1:00 – 3:00 p.m. CDT today at the 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago, IL.
SAN RAFAEL, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Sarah Cannon Research UK today announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation.
HOUSTON , June 23, 2014 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted.
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) ( www.BSDMedical.com ),
a leading provider of medical systems that utilize heat therapy to treat
cancer, today reported initiation of a Phase I/II study (HYPROSAR) using
hyperthermia, delivered using either the BSD-2000 Hyperthermia System
(BSD-2000) or the BSD-500 Hyperthermia System (BSD-500), combined with
proton radiotherapy to treat patients with unresectable soft tissue
SOUTH SAN FRANCISCO, CA --
Sign-up for Cannabis Science Initiates Pre-Clinical Studies on Cannabinoid Formulations in Neurological Diseases Including Sleep Disorders with the Highly Reputable Institute for Health and Science on Ageing - INRCA - in Italy investment picks
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.